TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study of 29 healthy adults found that a treatment combining temporary blood-pressure reduction with rhythmic whole-body vibration was associated with increased levels of several brain-derived proteins in the blood. The researchers say the results suggest enhanced protein clearance, but the study does not show that the treatment prevents or treats dementia.
Researchers in Finland found that a treatment combining temporary blood-pressure-lowering medication and rhythmic whole-body vibration was associated with increased levels of dementia-linked and other brain-derived proteins in the blood of 29 healthy adults. The study, published November 3 in Nature Communications, suggests the intervention may influence the brain’s fluid-clearance processes, but it does not establish that it prevents or treats dementia.
The study was conducted by researchers at the University of Oulu and Oulu University Hospital. Participants were healthy adults, and the team assessed the effects using multimodal MRI, physiological measurements and blood-based biomarkers originating in the brain. The treatment paired medication that temporarily lowered blood pressure with vibration stimulation intended to activate Piezo1 channels in blood vessels.
After treatment, blood levels of several soluble brain-derived proteins rose, including beta-amyloid 40 and 42 and GFAP. MRI and measurements of cerebrospinal-fluid circulation also showed changes in fluid flow and protein concentrations, including changes around large veins in the brain. The researchers interpret the rise in blood biomarkers as evidence consistent with proteins moving out of the brain; the measurements do not, by themselves, establish a future health benefit.
The team’s approach builds on animal research linking changes in blood pressure and vascular activity with cerebrospinal-fluid movement and waste clearance. In the new human study, the medication strengthened slow brain pulsations associated with fluid flow. The researchers said the combined treatment was linked to increased protein efflux, but the report does not establish how long the effect lasts or whether it changes disease risk.
Testing Brain Clearance While Awake
The findings offer an early human test of whether the brain’s clearance processes can be influenced while people are awake, rather than relying on the changes in blood pressure and brain pulsations associated with sleep. That matters because Alzheimer’s disease and other dementias are associated with the gradual accumulation of abnormal proteins, and researchers are looking for ways to understand and potentially affect that process.
For now, the result is a biological signal in a small group of healthy volunteers, not evidence of reduced dementia risk. A rise in blood protein levels after treatment may indicate movement from the brain, but it does not show that harmful proteins were removed in a way that improves memory, prevents deposits or slows disease. The study therefore supports further investigation, rather than a treatment recommendation.
Popular right now
Philips Café Aromis Automatic Espresso Machine with LatteGo Pro Milk System
Samsung 65-Inch The Frame Pro Neo QLED 4K TV (2026) Bundle with Modern Brown Bezel, HDMI Cables, and Home Theater Guide
Dyson V8 Cyclone Cordless Vacuum
As an affiliate, we earn on qualifying purchases.
From Sleep Biology to Stimulation
The brain’s waste-clearance activity is known to vary with sleep. As people fall asleep, blood pressure typically drops and slow vascular and respiratory pulsations become stronger. Those changes can increase cerebrospinal-fluid movement through brain tissue. The Finnish researchers used this established physiological relationship as a basis for testing whether related processes could be influenced during wakefulness.
Earlier mouse studies had linked temporarily lowering blood pressure with increased clearance of cerebrospinal fluid and the molecules it carries. Other animal research associated activation of Piezo1 channels with changes in meningeal lymphatic flow and lower beta-amyloid burden. The current study extends this line of research to humans, but it examined healthy adults rather than people with dementia or memory impairment.
Clinical Benefits Remain Untested
The study involved 29 healthy adults, and the source report does not provide evidence that participants had dementia-related symptoms or that treatment changed cognition. It remains unclear how durable the observed changes are, whether the same response would occur in older adults or people with early memory impairment, and what repeated treatment might do.
The report also does not establish whether the increase in blood proteins represents a lasting reduction in brain protein burden, or whether it could predict lower disease risk. The researchers describe the results as evidence suggesting enhanced clearance; they are not proof that the approach prevents, slows or treats dementia. Safety and effectiveness in patient populations require further study.
Studies in Early Memory Impairment
Kiviniemi said the researchers are planning follow-up studies with specialists to examine possible effects in people with early-stage memory impairment. Those studies would need to test clinical outcomes as well as changes in imaging and blood biomarkers, and clarify how long any effects last.
Until those results are available, the treatment remains an experimental research approach. The current findings do not support using the medication-and-vibration combination to prevent dementia, and the source report does not provide a timetable for the planned patient studies.
Key Questions
What treatment did the researchers test?
They combined medication that temporarily lowers blood pressure with rhythmic whole-body vibration intended to activate Piezo1 channels in blood vessels.
Who took part in the study?
The study involved 29 healthy adult volunteers. It did not test the treatment in people with dementia.
Does the study show that the treatment prevents Alzheimer’s disease?
No. The researchers reported changes in blood biomarkers and brain-fluid measurements, but the study did not show that the treatment prevents or slows Alzheimer’s disease or improves memory.
What happens next?
The researchers said they are planning follow-up studies with other experts to investigate possible effects in people with early-stage memory impairment. No timetable was specified in the report.
Source: news-medical.net
